What does BTM stand for?

Biotech Monthly (independent research firm)

This definition appears very rarely and is found in the following Acronym Finder categories:

Business, finance, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Behind-the-Meter (generators) Bell Telephone Number Benchmark Timing Methodology Beneath the Massacre (band) Best Tuning Memory (Sony) Betäubungsmittel (German: drugs) Betäubungsmittelmißbrauch (German: Drug Abuse, used in the police records) Big Thunder Mountain (Disney Theme Parks) Big Time Mafia (video game; graffiti gang) Big Trellis Model		Black Top Maintenance Blame the Media Blast Test Missile Bless This Mess Blog Ta Mère (French blog) Blood Temperature Monitoring Bluetooth Module (wireless technology) Boarding Team Boarding Team Member Boat Tail Match (ammunition)

Samples in periodicals archive:

David Miller, publisher of Biotech Monthly, a Seattle-based investment newsletter, said medical-devices companies are more popular with IPO investors now than are drug companies because the former tend to be closer to selling a product and have lower valuations.

Medical-device company seeks IPO to raise up to $85 million

AGROFOOD Biotech Monthly sounds like one of those publications featured on Have I Got News for You.

Informa is taking a bite at the GM cherry

David Miller, editor of Seattle-based Biotech Monthly newsletter, said that firms such as Clinical Advisors and Gerson Lehrman Group that make a living off of hooking up doctors with Wall Street firms "are still very heavily recruiting and insofar as I know did not have any significant disruption of their business.

Faster probe sought into research trials; Senator makes request; SEC ...

David Miller, president of Biotech Monthly, a Seattle-based industry newsletter, said Taxotere's results were well-received at last year's annual meeting of cancer doctors, and many oncologists remain skeptical about Provenge.

Study results positive for new cancer drug Dendreon's therapy for ...

People are confused, and they want answers," said David Miller of Biotech Monthly, a Seattle-based trade publication.

Dendreon's drug news befuddles investors

13 is the sort of thing that "happens all the time" in the biotech industry, said David Miller, president of Biotech Monthly, a Seattle-based newsletter.

Corixa stock busy before bad news Trading surge preceded cuts ...

David Miller, president of Biotech Monthly, who doesn't own Sonus shares, said he's surprised the company announced an acquisition that dilutes the value of its stock when it appears to have a clear path to approval of Tocosol.

Bothell's Sonus to buy French biotech firm

David Miller, president of Biotech Monthly in Seattle, said Wall Street probably would have given the company a bigger boost if ZymoGenetics had done the deal with a bigger name like Pfizer or Novartis, but with Serono "it's always nice to do business with people that you're already doing business with, and with whom you have a good working relationship.

Seattle biotech lands sweet Swiss deal ZymoGenetics gets partner ...